No black box warning on record for Fulphila

As of the latest FDA labeling reviewed, Fulphila (PEGFILGRASTIM-JMDB) does not carry a black box warning. Standard warnings and precautions still apply — see the full Fulphila medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS • Fatal splenic rupture: Evaluate patients who report left upper abdominal or shoulder pain for an enlarged spleen or splenic rupture. ( 5.1 ) • Acute respiratory distress syndrome (ARDS): Evaluate patients who develop fever, lung infiltrates, or respiratory distress. Discontinue Fulphila in patients with ARDS. ( 5.2 ) • Serious allergic reactions, including anaphylaxis:

No black box warning on record for Fulphila

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS • Fatal splenic rupture: Evaluate patients who report left upper abdominal or shoulder pain for an enlarged spleen or splenic rupture. ( 5.1 ) • Acute respiratory distress syndrome (ARDS): Evaluate patients who develop fever, lung infiltrates, or respiratory distress. Discontinue Fulphila in patients with ARDS. ( 5.2 ) • Serious allergic reactions, including anaphylaxis:

Fulphila Black Box Warning

No black box warning on record for Fulphila

Other warnings & precautions

Fulphila Black Box Warning

No black box warning on record for Fulphila

Other warnings & precautions